Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective

Area of Science:

• Biochemistry and Medicinal Chemistry
• Enzyme Inhibition and Drug Discovery

Background:

• Overexpression of arginase (ARG) isoforms, ARG1 and ARG2, is implicated in cardiovascular diseases, immune disorders, and cancer.
• Current ARG inhibitors often lack isoform selectivity, hindering therapeutic applications and potentially causing side effects.
• Targeting specific ARG isoforms is crucial for developing effective treatments without disrupting essential physiological functions.

Purpose of the Study:

• To provide a comprehensive overview of existing arginase inhibitor generations.
• To analyze the structural characteristics of ARG1 and ARG2 binding sites for novel inhibitor design.
• To discuss strategies for developing potent, selective ARG inhibitors with favorable pharmacokinetic profiles and low toxicity.

Main Methods:

• Review of existing literature on arginase inhibitors and their generations.
• Analysis of structural features and binding site plasticity of ARG1 and ARG2.
• Evaluation of ongoing preclinical and clinical studies of selected ARG inhibitors.

Main Results:

• Existing arginase inhibitors generally lack sufficient isoform selectivity.
• Structural analysis reveals potential for designing novel inhibitors targeting specific binding patterns within ARG1 and ARG2.
• Ongoing studies show progress but also highlight challenges in developing potent and selective ARG inhibitors.

Conclusions:

• Developing isoform-selective arginase inhibitors is critical for therapeutic advancement.
• Understanding ARG1 and ARG2 binding site dynamics is key to designing next-generation inhibitors.
• Medicinal chemistry strategies are essential to accelerate the discovery of effective and safe arginase-targeted therapies.